Stocks · News reference
Niki BioSolutions, Inc., a Delaware corporation (the "Company," "Niki," "we," "our," or "us"), has entered into an at-the-market issuance sales agreement, dated October 9, 2026
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences Corp., received approval from the New York State Department of Health to expand the specimen types for its APOE Genotyping test.
Niki BioSolutions, Inc. announced that its subsidiary, DiamiR Biosciences, has entered into an agreement to provide apolipoprotein E (APOE) genotyping services for Charter Research.
Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki" or the "Company"), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that